201 related articles for article (PubMed ID: 7515445)
21. Early identification of therapeutic failure in nonseminomatous germ cell tumors by assessing serum tumor marker decline during chemotherapy: still not ready for routine clinical use.
Toner GC
J Clin Oncol; 2004 Oct; 22(19):3842-5. PubMed ID: 15302908
[No Abstract] [Full Text] [Related]
22. Retroperitoneal lymphadenectomy and aggressive chemotherapy in nonbulky clinical Stage II nonseminomatous germinal testis tumors.
Pizzocaro G; Zanoni F; Milani A; Piva L; Salvioni R; Pasi M; Pilotti S; Monfardini S
Cancer; 1984 Mar; 53(6):1363-8. PubMed ID: 6198070
[TBL] [Abstract][Full Text] [Related]
23. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
Aparicio J; Sánchez-Muñoz A; Ochenduszko S; Gumà J; Fernández-Aramburo A; García Del Muro X; Quiroga V; Sastre J; Alonso-Gordoa T; Sagastibelza N; Maroto P; Gómez de Liaño A; Vázquez S; Diz P; Durán I; Domenech M; Pinto A; Hernández A; González-Billalabeitia E; Terrasa J
J Urol; 2019 Oct; 202(4):742-747. PubMed ID: 31163007
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors in metastatic nonseminomatous germ cell tumours.
Hanson PR; Belitsky P; Millard OH; Lannon SG
Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
[TBL] [Abstract][Full Text] [Related]
25. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
Beck SD; Patel MI; Sheinfeld J
J Urol; 2004 Jan; 171(1):168-71. PubMed ID: 14665869
[TBL] [Abstract][Full Text] [Related]
26. Nonpalpable testicular pure seminoma with elevated serum alpha-fetoprotein presenting with retroperitoneal metastasis: a case report.
Iwatsuki S; Naiki T; Kawai N; Etani T; Iida K; Ando R; Nagai T; Okada A; Tozawa K; Sugiyama Y; Yasui T
J Med Case Rep; 2016 May; 10(1):114. PubMed ID: 27150447
[TBL] [Abstract][Full Text] [Related]
27. [Retroperitoneal surgery in the treatment of germ-cell tumors of the testis: retroperitoneal lymph node dissection (RPLND)].
Nicolai N; Necchi A; Piva L; Stagni S; Catanzaro MA; Biasoni D; Milani A; Torelli T; Salvioni R
Urologia; 2010; 77(2):84-7. PubMed ID: 20890864
[TBL] [Abstract][Full Text] [Related]
28. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
[TBL] [Abstract][Full Text] [Related]
29. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.
Aass N; Klepp O; Cavallin-Stahl E; Dahl O; Wicklund H; Unsgaard B; Baldetorp L; Ahlström S; Fosså SD
J Clin Oncol; 1991 May; 9(5):818-26. PubMed ID: 1707957
[TBL] [Abstract][Full Text] [Related]
31. Stage II nonseminomatous germ cell tumors of the testis: an analysis of treatment options in patients with low volume retroperitoneal disease.
Socinski MA; Garnick MB; Stomper PC; Fung CY; Richie JP
J Urol; 1988 Dec; 140(6):1437-41. PubMed ID: 2848138
[TBL] [Abstract][Full Text] [Related]
32. Clinical use of serum TRA-1-60 as tumor marker in patients with germ cell cancer.
Lajer H; Daugaard G; Andersson AM; Skakkebaek NE
Int J Cancer; 2002 Jul; 100(2):244-6. PubMed ID: 12115576
[TBL] [Abstract][Full Text] [Related]
33. Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA).
Klepp O; Flodgren P; Maartman-Moe H; Lindholm CE; Unsgaard B; Teigum H; Fosså SD; Paus E
Ann Oncol; 1990 Jul; 1(4):281-8. PubMed ID: 1702312
[TBL] [Abstract][Full Text] [Related]
34. Importance of a new tumor marker TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors.
Gels ME; Marrink J; Visser P; Sleijfer DT; Droste JH; Hoekstra HJ; Andrews PW; Schraffordt Koops H
Ann Surg Oncol; 1997 Jun; 4(4):321-7. PubMed ID: 9181232
[TBL] [Abstract][Full Text] [Related]
35. [The role of tumor markers in the treatment of germ cell tumor].
Niwakawa M; Tobisu K
Gan To Kagaku Ryoho; 2001 Aug; 28(8):1159-65. PubMed ID: 11525037
[TBL] [Abstract][Full Text] [Related]
36. [Unusual development of nonseminomatous germ cell tumors of the testis (NSGCT)].
Caty A; Depadt G; Feutry ML
Bull Cancer; 1997 Aug; 84(8):796-9. PubMed ID: 9339184
[TBL] [Abstract][Full Text] [Related]
37. A graphical method to analyze serum tumor marker decay in nonseminomatous testis tumors.
Lo RK; Johnson DE
J Urol; 1984 May; 131(5):896-8. PubMed ID: 6200617
[TBL] [Abstract][Full Text] [Related]
38. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
[TBL] [Abstract][Full Text] [Related]
39. Primary chemotherapy: how does it compare with surgery?
Horwich A
Semin Urol Oncol; 1996 Feb; 14(1):34-5. PubMed ID: 8833387
[TBL] [Abstract][Full Text] [Related]
40. Experience with serum alpha-fetoprotein and human chorionic gonadotropin in non-seminomatous testicular tumors.
Fowler JE; Taylor G; Blom J; Stutzman RE
J Urol; 1980 Sep; 124(3):365-8. PubMed ID: 6159485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
